iiinova — where your digital self keeps evolving

The OncoAlert Network 🚨 @oncoalert.bsky.social · 15h

This week’s OncoAlert 🚨 Newsletter is OUT! Packed with the latest updates in oncology. subscribe here 👉 buff.ly/N5gYtAc This week's must-reads: 🔸 Spotlight: Giredestrant + everolimus in ER+/HER2− ABC, PFS HR 0.38 in ESR1m (NEJM) 🔸 FDA: belzutifan + lenvatinib approved in ccRCC;

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 01/10/2026

Giredestrant plus Everolimus in Advanced Breast Cancer Could targeting both ER and PI3K–AKT–mTOR pathways help overcome endocrine resistance? 👇 www.nejm.org/doi/full/10....

010

The OncoAlert Network 🚨 @oncoalert.bsky.social · 30/09/2026

Why do some TNBC tumors respond to immunotherapy🧪 while others rapidly develop resistance? www.cell.com/cell-reports... A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics

001

The OncoAlert Network 🚨 @oncoalert.bsky.social · 29/09/2026

🚨 Join us at the 2026 International Symposium of Gastrointestinal Oncology (#ISGIO2026), October 2–3, 2026! 🆓 FREE registration with code: ONCOALERT 👉 Register: www.gotoper.com/courses/meet... This multidisciplinary program covers the latest advances in GI cancer research and biomarkers

020

The OncoAlert Network 🚨 @oncoalert.bsky.social · 29/09/2026

Dear GU Colleagues at #ASTRO26 ! Join us at the first LPCCC – Localised Prostate Cancer Consensus Conference, where challenging and unresolved questions in Prostate Cancerwill be discussed, debated and brought into focus. #LPCCC27 JUST NOW CALL FOR ABSTRACTS ARE OPEN apccc.org/call-for-abs...

001

The OncoAlert Network 🚨 @oncoalert.bsky.social · 28/09/2026

In Collaboration with our partners at ASTRO we continue our coverage of #ASTRO26 🚨 SIX-YEAR OVERALL SURVIVAL OF NIVOLUMAB FOLLOWING STEREOTACTIC ABLATIVE RADIOTHERAPY IN EARLY-STAGE NON-SMALL CELL LUNG CANCER: RANDOMIZED I-SABR TRIAL Presented by Dr. Joe Chang🇺🇸

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 28/09/2026

In Collaboration with our partners at ASTRO we continue our coverage of #ASTRO26 🚨 LBA 03 - SWOG S1827/MAVERICK: A RANDOMIZED PHASE III TRIAL OF BRAIN MRI SURVEILLANCE WITH AND WITHOUT PROPHYLACTIC CRANIAL IRRADIATION (PCI) FOR SMALL-CELL LUNG CANCER (SCLC) Presented by Dr. Paul Brown 🇺🇸

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 28/09/2026

In Collaboration with our partners at ASTRO we continue our coverage of #ASTRO26 🚨 STEREOTACTIC BODY RADIATION THERAPY (SBRT) AND COMPREHENSIVE METASTASIS-DIRECTED THERAPY FOR EWING SARCOMA PATIENTS ENROLLED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 25/09/2026

🚨 FDA Priority Review granted for durvalumab plus neoadjuvant enfortumab vedotin in muscle-invasive #BladderCancer : VOLGA Update Source: AstraZeneca Submission is supported by VOLGA results showing statistically significant and clinically meaningful improvements in event-free survival and OS

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 25/09/2026

What if a missed cancer diagnosis could cost you 8 years of life? 🚨 On this #WeekinOncology #Melanoma by OncoAlert🚨, our #OncoAlertAF colleagues Dr. Mario Balsa 🇪🇸 discusses an article out on Nature communications www.nature.com/articles/s41...

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 24/09/2026

FDA 🇺🇸 News: LITESPARK-011 Update in #kidneyCancer Source: FDA www.fda.gov/drugs/resour... On September 24, 2026, the FDA🇺🇸 approved belzutifan plus lenvatinib for adults with advanced renal cell carcinoma containing a clear cell component after PD-1/PD-L1 inhibitor treatment. In the LITESPARK-011

001

The OncoAlert Network 🚨 @oncoalert.bsky.social · 24/09/2026

📢 Join us at the 44th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow 📅 November 11–13, 2026 (NY, NY🇺🇸 ) REGISTER 👉 buff.ly/b5A7hsf HYBRID MEETING (Online and In Person) 🚨 FREE🆓 REGISTRATION with Code: OncoAlert

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 24/09/2026

Join us at 2026 International Symposium of Gastrointestinal Oncology on October 2–3, 26 🚨 FREE🆓 REGISTRATION with Code: ONCOALERT REGISTER 👉 buff.ly/Rld9coM

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 24/09/2026

Can a blood🩸 test detect cancer earlier—but still fail to demonstrate clinical utility? www.nejm.org/doi/full/10.... Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 23/09/2026

FDA News: REFOCUS Update in #Cholangiocarcinoma On September 23, 2026, the FDA🇺🇸 approved lirafugratinib for adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harboring FGFR2🧬 fusions or rearrangements. www.fda.gov/drugs/resour...

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 23/09/2026

What does 6 years of follow-up tell us about 1 year of adjuvant olaparib? The OlympiA trial continues to show meaningful improvements in disease-free and overall survival in high-risk, HER2-negative early #BreastCancer

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 23/09/2026

This week’s OncoAlert 🚨 Newsletter is OUT ^ packed with the latest in Oncology Don’t miss the latest updates—register to get it 👉 buff.ly/N5gYtAc The new ABC8 guidelines update advanced breast cancer care worldwide. An AI tool helps predict who benefits from immunotherapy in lung cancer.

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 22/09/2026

The OncoAlert HORIZONS Series: Breast Cancer What happens when Watch & Wait fails? How Mechanism based therapies are rewriting Cancer Care WATCH THE ENTIRE VIDEO HERE👉 youtu.be/Efk2mf0RnNA?...

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 21/09/2026

Dear Colleagues, Join @OncoAlert 🚨 LIVE in FLORENCE Italy Oct 9–10, for the 2nd International Multidisciplinary Consensus on Integrating Radiation Therapy with New Systemic Treatments (endorsed by ESTRO) REGISTER HERE 👉 buff.ly/I8wKRpo

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 21/09/2026

📣 Early Bird Registration for #IKCSNA26 Now Open Join us for the 2026 International Kidney Cancer Symposium (IKCS): North America www.kidneycancer.org/event/2026-i...

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 21/09/2026

This week's OncoAlert 🚨 Newsletter is packed with practice-changing data: REGISTER TO GET IT 👉 buff.ly/N5gYtAc → Tambotatug pelitecan nearly doubled response rates over topotecan in relapsed small-cell lung cancer — 59.1% vs 9.7% — with fewer grade ≥3 events (NEJM)

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 20/09/2026

Join us at 2026 International Symposium of Gastrointestinal Oncology on October 2–3, 26 🚨 FREE🆓 REGISTRATION with Code: ONCOALERT REGISTER 👉 buff.ly/Rld9coM This multidisciplinary program focuses on the latest advances in GI cancer research, biomarkers, and personalized treatment.

010

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/09/2026

📢 Join us at the 44th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow 📅 November 11–13, 2026 (NY, NY🇺🇸 ) REGISTER 👉 buff.ly/3G9pRP6 HYBRID MEETING (Online and In Person) 🚨 FREE🆓 REGISTRATION with Code: OncoAlert

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/09/2026

DAY Two | OncoAlert at #GUARDSymposium2026 🇪🇸 🧬 How do we break through the IO + TKI plateau in kidney cancer? Dr. Guillermo de Velasco 🇪🇸 from Hospital Universitario 12 de Octubre, Madrid, maps four emerging strategies in advanced #RCC — HIF-2α inhibition, T-cell engagers/CAR-T

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/09/2026

DAY TWO | OncoAlert at #GUARDSymposium2026 🇪🇸 🧬 Does every patient with HRR-mutated prostate cancer need a PARP inhibitor plus ARPI — and does which PARPi you choose matter? Dr. Charles Ryan 🇺🇸 from Memorial Sloan Kettering Cancer Center, New York, delivers a keynote lecture on PARP inhibitor mgt.

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/09/2026

DAY THREE | OncoAlert at #GUARDSymposium2026 🇪🇸 🧬 What comes after enfortumab vedotin in urothelial cancer? Dr. Jonathan E. Rosenberg 🇺🇸 from Memorial Sloan Kettering Cancer Center, New York, looks ahead to the next wave of ADCs and the biomarkers that will guide their use in #UrothelialCarcinoma 🔬

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/09/2026

DAY THREE | OncoAlert at #GUARDSymposium2026 🇪🇸 🧬 With no randomised evidence in second line, how should clinicians sequence therapy after EV+pembrolizumab in advanced bladder cancer? Dr. Urbano Anido 🇪🇸 from Complexo Hospitalario Universitario de Santiago

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/09/2026

DAY 3 | OncoAlert at #GUARDSymposium2026 🇪🇸 🧬 Can we safely de-escalate perioperative therapy in muscle-invasive bladder cancer? Dr. Andrea Necchi 🇮🇹 reviews the evolving standard of care for #MIBC — from sandwich (neoadjuvant + adjuvant) immunotherapy to next-generation bladder-sparing strategies

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/09/2026

DAY THREE | OncoAlert at #GUARDSymposium2026 🇪🇸 🧬 Is it finally time for ctDNA to guide treatment decisions in bladder cancer? Dr. Sara Coca Membribes 🇬🇧 from Barts Cancer Institute, London, walks through the full biomarker landscape shaping therapy in #BladderCancer

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 18/09/2026

Are we truly personalizing treatment for premenopausal women with HR+/HER2− early breast cancer—or still applying evidence largely built around postmenopausal populations? 🎗️ www.sciencedirect.com/science/arti...

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/09/2026

🚨 DAY 2 | #GUARDSymposium2026 Coverage by OncoAlert After progression, what's the right next line—TKI, IO rechallenge, or a HIF-2a combination? The evidence isn't equal across options. 🧭 At #GUARDSymposium2026, Dr. Javier Molina 🇪🇸, Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal

010

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/09/2026

🚨 DAY 2| #GUARDSymposium2026 Coverage by OncoAlert CAIX or PSMA—which molecular PET target actually changes staging and treatment selection in clear-cell RCC? 🧬 At #GUARDSymposium2026, Dra. Andrea Luna Mass 🇩🇪, Nuclear Medicine, University Hospital Carl Gustav Carus, Germany

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/09/2026

🚨 DAY 2/| #GUARDSymposium2026 Coverage by OncoAlert Adjuvant pembrolizumab is now standard of care in high-risk RCC—so how do we build on it, and who should get belzutifan on top? #GUARDSymposium2026, Dr. Roberto Iacovelli 🇮🇹, Servicio de Oncología Médica, Policlinico Universitario Agostino Gemelli

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/09/2026

🚨 Day One at #GUARDSymposium2026 | OncoAlert Coverage 🧬 Can machine learning help us understand metastatic risk in prostate cancer? Sonia Macía 🇪🇸 presents MET-score—an explainable machine-learning approach using transcriptomic data to model metastatic risk in #ProstateCancer

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/09/2026

🚨 DAY 2 | #GUARDSymposium2026 Coverage by OncoAlert PSMA-targeted radioligand therapy has transformed mCRPC care—so what does implementation look like as the next wave of trials arrives? ☢️ At #GUARDSymposium2026, Dr. David Kersting 🇩🇪, Essen University Hospital, Germany

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 17/09/2026

🚨 DAY TWO | OncoAlert at #GUARDSymposium2026 🎯 Oligometastatic mHSPC is entering a new imaging era. Dr. Nicholas James 🇬🇧 , The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, Sutton, UK, takes on a key clinical question:

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/09/2026

🚨 DAY 1 | #GUARDSymposium2026 Coverage by OncoAlert Can PSMA PET/CT redefine staging in high-risk localized #ProstateCancer —or are there still blind spots we can’t ignore? 🔬 At #GUARDSymposium2026, Dra. Iratxe Fernández 🇪🇸, Servicio de Medicina Nuclear, Hospital Universitario de Cruces, Bilbao

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/09/2026

🚨 DAY ONE | OncoAlert at #GUARDSymposium2026 🇪🇸 🧬 What drives prostate cancer to become more aggressive? Dr. Arkaitz Carracedo 🇪🇸 from CIC bioGUNE, Bilbao, presents two studies exploring the molecular drivers underlying the acquisition of aggressive features in #ProstateCancer

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/09/2026

🚨 DAY 1 | #GUARDSymposium2026 🇪🇸 Can SBRT redefine radiotherapy for high-risk prostate cancer? At #GUARDSymposium2026, Dr. Giulia Marvaso🇮🇹 from Istituto Europeo di Oncologia and Università degli Studi di Milano explores the evolving role of SBRT in high-risk prostate cancer.

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/09/2026

🚨 DAY 1 | #GUARDSymposium2026 Coverage by OncoAlert What if early salvage radiotherapy can deliver the same oncologic control as adjuvant RT—with fewer side effects? Dr. Luca Nicosia🇮🇹 discusses early salvage RT ☢️ after radical prostatectomy in high-risk localized or locally adv #ProstateCancer

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 16/09/2026

🚨 GUARD SYMPOSIUM 2026 — FREE VIRTUAL REGISTRATION FOR COLLEAGUES IN LATAM! 🌎 TODAY (HYBRID MEETING) 📅 September 16–18, 2026 (STARTS TODAY) 📍 Madrid, Spain & Online 🔗 REGISTER HERE👉 buff.ly/7heG7rX 🇱🇦 Special offer for colleagues from LATAM: Use the code: ONCOALERTGUARD2026 for FREE registration!

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 15/09/2026

Dear Colleagues, Presenting OncoAlert Horizons | Focus: Breast Cancer Educational Series 🚨 In this session, we explore: The 1st Line Reset and the New Sequencing Problem — what do we want to achieve in HER2+ metastatic #BreastCancer? 🧑‍⚕️ Session Faculty: Dr. Javier Cortes Dr. Elisa Agostinetto

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 15/09/2026

FDA News📰 : daraxonrasib in hashtag#PancreaticCancer Source: Revolution Medicines The FDA 🇺🇸 recently granted Breakthrough Therapy Designation to Revolution Medicines' RASONQUE (daraxonrasib) combined with gemcitabine/nab-paclitaxel for treatment-naïve metastatic pancreatic adenocarcinoma

200

The OncoAlert Network 🚨 @oncoalert.bsky.social · 15/09/2026

Can one bispecific ADC actually work across three biologically distinct breast cancer subtypes? www.annalsofoncology.org/article/S092... Safety & antitumor activity of the first-in-class EGFR–HER3 bispecific ADC iza-bren (BL-B01D1) in patients with pretreated locally Adv/ metastatic breast cancer

021

The OncoAlert Network 🚨 @oncoalert.bsky.social · 14/09/2026

🚨 GUARD SYMPOSIUM 2026 — FREE REGISTRATION FOR LATAM COLLEAGUES HAPPENING IN JUST 2 DAYS 📅 September 16–18, 2026 (NEXT WEEK) 📍 Madrid, Spain | Hybrid Meeting 🔗 REGISTER HERE👉 buff.ly/7heG7rX

000

The OncoAlert Network 🚨 @oncoalert.bsky.social · 14/09/2026

🚨 Could B7-H3 targeting represent a meaningful new direction in relapsed small-cell lung cancer? #WCLC26 👉 NEJM Article www.nejm.org/doi/full/10.... Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy

010

The OncoAlert Network 🚨 @oncoalert.bsky.social · 11/09/2026

The 🚨 OncoAlert TOP 10 — #WCLC26 🌐 👉Advanced #SCLC & #Mesothelioma 🇰🇷 We’re kicking off our OncoAlert TOP 10 for #WCLC26 with a focus on Advanced Small Cell #LungCancer ( #SCLC ) and Mesothelioma🫁

001

The OncoAlert Network 🚨 @oncoalert.bsky.social · 11/09/2026

September 11 is one of our worst days that brought out the best in us🇺🇸 United We Stand, Lets Roll!

001

The OncoAlert Network 🚨 @oncoalert.bsky.social · 11/09/2026

Could NECTIN4 localization—and not just expression—help us identify which patients are most likely to benefit from enfortumab vedotin? aacrjournals.org/clincancerre... Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting eV Response

010

The OncoAlert Network 🚨 @oncoalert.bsky.social · 10/09/2026

🚨 GUARD SYMPOSIUM 2026 — FREE REGISTRATION FOR COLLEAGUES IN LATAM! 🌎 📅 September 16–18, 2026 (NEXT WEEK) 📍 Madrid, Spain | Hybrid Meeting 🔗 REGISTER HERE👉 buff.ly/7heG7rX 🇱🇦 Special FREE Registration for LATAM: Use the code: ONCOALERTGUARD2026

000